Serum Adiponectin Level Association with Breast Cancer Risk: Evidence from a Case-Control Study

  • Ahmed, Syed Danish Haseen (Biochemistry, medicine, dow medical college, DOW university of health sciences) ;
  • Khanam, Aziza (Department of Biochemistry, University of Karachi) ;
  • Sultan, Naheed (Department of Surgery, Dow Medical College and Civil Hospital Karachi, Dow University of Health Sciences) ;
  • Idrees, Farah (Department of Surgery, Dow Medical College and Civil Hospital Karachi, Dow University of Health Sciences) ;
  • Akhter, Naheed (Department of Biochemistry, University of Karachi)
  • Published : 2015.07.13


Background: Adiponectin is a protein, synthesized by adipose tissue, which has a questionable role in breast cancer pathogenesis. This study focused on serum levels of adiponectin among cases and controls, and its possible association with breast cancer risk. Materials and Methods: This case-control study covered 175 diagnosed breast cancer patients with positive histopathology from Breast Clinic, surgical unit-1, Civil Hospital, Karachi and 175 healthy controls from various screening programs. Blood samples were obtained after an overnight fast and later analyzed. Results: Fasting blood glucose was significantly raised, while serum adiponectin was significantly decreased in breast cancer cases when compared to control subjects. To find the precise influence of serum adiponectin on the risk of breast cancer, subjects were divided in to quartiles based on serum levels of adiponectin. It is observed that risk of breast cancer decreased with rising quartile. Q2 (25th-50th) had the highest OR=1.76 (CI: 0.93- 3.34), Q3 (50th-75th) has OR= 0.89 (CI: 0.48-1.64), while subjects in the highest quartile Q4 (>75th) had significantly (p< 0.05) decreased risk of breast cancer having OR=0.06 (CI: 0.02-0.15), when compared to the lowest quartile. Conclusions: We demonstrated a statistically significant association of elevated serum adiponectin with decreased risk of breast cancer. This signifies a protective role of adiponectin via an intricate mechanism of masking mitogenic growth factors in breast carcinogenesis.


Adiponectin;breast cancer;risk


  1. Bhurgri Y (2004). Karachi cancer registry data--implications for the national cancer control program of pakistan. Asian Pac J Cancer Prev, 5, 77-82.
  2. Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer, 4, 579-91.
  3. Dean AG, Sullivan KM, Soe MM (2014). Openepi: open source epidemiologic statistics for public health, version., updated September 01, 2014. Accessed September 04, 2014.
  4. Ferlay J, Soerjomataram I, Dikshit R, et al (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136, 359-86.
  5. Haseen SD, Khanam A, Sultan N, et al (2015). Elevated fasting blood glucose is associated with increased risk of breast cancer: outcome of case-control study conducted in karachi, Pakistan. Asian Pac J Cancer Prev, 16, 675-8.
  6. IBM Corp. (2011). IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.
  7. Kadowaki T, Yamauchi T (2005). Adiponectin and adiponectin receptors. Endocr Rev, 26, 439-51.
  8. Kadowaki T, Yamauchi T, Kubota N, et al (2006). Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest, 116, 1784-92.
  9. Kang JH, Yu BY, Youn DS (2007). Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci, 22, 117-21.
  10. Karimi N, Roshan VD (2013). Change in adiponectin and oxidative stress after modifiable lifestyle interventions in breast cancer cases. Asian Pac J Cancer Prev, 14, 2845-50.
  11. Kelesidis I, Kelesidis T, Mantzoros CS (2006). Adiponectin and cancer: a systematic review. Br J Cancer, 94, 1221-5.
  12. Keramatinia A, Mousavi-Jarrahi SH, Hiteh M, Mosavi-Jarrahi A. (2014). Trends in incidence of breast cancer among women under 40 in Asia. Asian Pac J Cancer Prev, 15, 1387-90.
  13. Korner A, Pazaitou-Panayiotou K, Kelesidis T, et al (2007). Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab, 92, 1041-8.
  14. Leclere B, Molinie F, Tretarre B, et al (2013). Trends in incidence of breast cancer among women under 40 in seven European countries: a GRELL cooperative study. Cancer Epidemiol, 37, 544-9.
  15. Shahar S, Salleh RM, Ghazali AR, Koon PB, Mohamud, WN (2010). Roles of adiposity, lifetime physical activity and serum adiponectin in occurrence of breast cancer among Malaysian women in Klang Valley. Asian Pac J Cancer Prev, 11, 61-6.
  16. Stattin P, Bjor O, Ferrari P (2007). Prospective study of hyperglycemia and cancer risk. Diabetes Care, 30, 561-7.
  17. Torre LA, Bray F, Siegel RL, et al (2015). Global cancer statistics, 2012. CA: A Cancer J Clinicians, 65, 87-108.
  18. Wang Y, Lam KS, Xu JY, et al (2005) Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem, 280, 18341-7.
  19. Yamauchi T, Kamon J, Ito Y, et al (2003). Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 423, 762-9.

Cited by

  1. Impact of Chemotherapy on Diet and Nutritional Status of Women with Breast Cancer: A Prospective Study vol.11, pp.6, 2016,
  2. Serum adiponectin in breast cancer vol.97, pp.29, 2018,
  3. Association of serum adiponectin with breast cancer vol.98, pp.6, 2019,